These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 31668092)

  • 1. More is needed to complement the available therapies of spinal muscular atrophy.
    Singh RN
    Future Med Chem; 2019 Nov; 11(22):2873-2876. PubMed ID: 31668092
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene therapy for spinal muscular atrophy.
    Gowda VL; Jungbluth H; Wraige E
    Arch Dis Child Educ Pract Ed; 2023 Oct; 108(5):347-350. PubMed ID: 37423714
    [No Abstract]   [Full Text] [Related]  

  • 3. Inpatient rehabilitation admission for a patient with spinal muscular atrophy status post gene therapy.
    Omura JC; Freeman CL; Perlman SJ; Fuentes MM
    PM R; 2023 Oct; 15(10):1361-1362. PubMed ID: 36655390
    [No Abstract]   [Full Text] [Related]  

  • 4. Deciphering spinal muscular atrophy: the need for more research.
    Farrar MA; Kariyawasam DS
    Lancet Neurol; 2024 Feb; 23(2):134-136. PubMed ID: 38267176
    [No Abstract]   [Full Text] [Related]  

  • 5. Living with spinal muscular atrophy while working in critical care.
    Wehner L; Malhotra A; Orr J
    Lancet Respir Med; 2024 Jul; 12(7):510-512. PubMed ID: 38851195
    [No Abstract]   [Full Text] [Related]  

  • 6. A Paradigm Shift for the Management of Critically Ill Patients With Spinal Muscular Atrophy.
    Bach JR; Palmieri JL
    Respir Care; 2023 Oct; 68(10):1481-1482. PubMed ID: 37722737
    [No Abstract]   [Full Text] [Related]  

  • 7. [Spinal Muscular Atrophy with early presentation, perspectives for its treatment in Chile].
    Valdebenito Parra C; Prado Atlagic F; Huerta Armijo A; Aros Aránguiz S
    Andes Pediatr; 2024 Feb; 95(1):110-112. PubMed ID: 38587352
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene-based therapies of spinal muscular atrophy: a piece of history of medicine].
    Braun S
    Med Sci (Paris); 2020 Feb; 36(2):141-146. PubMed ID: 32129750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments in spinal muscular atrophy: an overview of currently available data.
    Ramdas S; Servais L
    Expert Opin Pharmacother; 2020 Feb; 21(3):307-315. PubMed ID: 31973611
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Qiao Y; Chi Y; Gu J; Ma Y
    Brain Sci; 2023 Oct; 13(10):. PubMed ID: 37891788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy.
    Ottesen EW; Singh NN; Luo D; Kaas B; Gillette BJ; Seo J; Jorgensen HJ; Singh RN
    Nucleic Acids Res; 2023 Jul; 51(12):5948-5980. PubMed ID: 37026480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Context of a Critical Exon of Spinal Muscular Atrophy Gene.
    Singh NN; O'Leary CA; Eich T; Moss WN; Singh RN
    Front Mol Biosci; 2022; 9():928581. PubMed ID: 35847983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.
    Dominguez CE; Cunningham D; Venkataramany AS; Chandler DS
    Hum Genet; 2022 Feb; 141(2):239-256. PubMed ID: 35088120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome.
    Ottesen EW; Luo D; Singh NN; Singh RN
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Whole-Exome Sequencing With MLPA Revealed Variants in Two Genes in a Patient With Combined Manifestations of Spinal Muscular Atrophy and Duchenne Muscular Dystrophy.
    Xia Y; Feng Y; Xu L; Chen X; Gao F; Mao S
    Front Genet; 2021; 12():605611. PubMed ID: 33777091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.
    Singh NN; Hoffman S; Reddi PP; Singh RN
    Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166063. PubMed ID: 33412266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
    Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
    Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
    Singh RN; Ottesen EW; Singh NN
    Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA in spinal muscular atrophy: therapeutic implications of targeting.
    Singh RN; Seo J; Singh NN
    Expert Opin Ther Targets; 2020 Aug; 24(8):731-743. PubMed ID: 32538213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.